Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study to track Eltrombopag's effectiveness in ITP patients

NCT ID NCT07587723

Recruiting now Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study looks at how eltrombopag is actually used and how well it works in patients with immune thrombocytopenia (ITP) who have already tried steroids. Researchers will collect data from healthcare providers in the US, UK, and Germany, focusing on platelet count improvements within 12 weeks. The goal is to understand real-world treatment patterns and outcomes, not to test a new drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
eltrombopag
What this could lead to
If successful, this study could provide real-world evidence on how well eltrombopag works for immune thrombocytopenia outside of clinical trials.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient selection and other factors. It does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE THROMBOCYTOPENIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Novartis

    RECRUITING

    Basel, CH-4056, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.